Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in the Management of Advanced and Metastatic Urothelial Carcinoma
Gavin Hui(University of California, Los Angeles), Alexandra Drakaki(University of California, Los Angeles), Christopher Hannigan(University of California, Los Angeles), Dayna J Isaacs, Allan J. Pantuck(University of California System), Dimitrios Stefanoudakis(APLA Health), Yuliya Zektser(University of California, Los Angeles)
Cited by 6
Related Papers
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2021|411
Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma
|JCI Insight|2017|129